Kayne Anderson Rudnick Investment Management LLC Fate Therapeutics Inc Transaction History

Kayne Anderson Rudnick Investment Management LLC

$41.6 Billion
Q4 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 12, 2022	SELL	$17.78 - $42.39 $284 - $678	-16 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $474 - $964	16 New	16 $1,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

108M

Call Options Held

79.2K

Put Options Held

Redmile Group, LLC San Francisco, CA

12.9M
Shares

$18.3 Million
1.66% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$14.7 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$14.4 Million
0.0% of portfolio
Bellevue Group Ag Kuesnacht, V8

4.84M
Shares

$6.87 Million
0.16% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

4.38M
Shares

$6.22 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.

Account